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Abstract
Background: IGF binding protein-3 (IGFBP-3) regulates the bioavailability of insulin-like growth
factors I and II, and has both anti-proliferative and pro-apoptotic properties. Elevated plasma
IGFBP-3 has been associated with reduced risk of colorectal cancer (CRC), but the role of tissue
IGFBP-3 is not well defined. We evaluated the association between tissue or plasma IGFBP-3 and
risk of colorectal adenomas or low apoptosis.
Methods: Subjects were consenting patients who underwent a clinically indicated colonoscopy at
UNC Hospitals and provided information on diet and lifestyle. IGFBP-3 mRNA in normal colon was
assessed by real time RT-PCR. Plasma IGFBP-3 was measured by ELISA and apoptosis was
determined by morphology on H & E slides. Logistic regression was used to compute odds ratio
(OR) and 95% confidence intervals.
Results:  We observed a modest correlation between plasma IGFBP-3 and tissue IGFBP-3
expression (p = 0.007). There was no significant association between plasma IGFBP-3 and
adenomas or apoptosis. Tissue IGFBP-3 mRNA expression was significantly lower in cases than
controls. Subjects in the lowest three quartiles of tissue IGFBP-3 gene expression were more likely
to have adenomas. Consistent with previous reports, low apoptosis was significantly associated
with increased risk of adenomas (p = 0.003). Surprisingly, local IGFBP-3 mRNA expression was
inversely associated with apoptosis.
Conclusion: Low expression of IGFBP-3 mRNA in normal colonic mucosa predicts increased risk
of adenomas. Our findings suggest that local IGFBP-3 in the colon may directly increase adenoma
risk but IGFBP-3 may act through a pathway other than apoptosis to influence adenoma risk.
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Background
The insulin-like growth factors, IGF-I and IGF-II, and their
corresponding receptors play important roles in prolifera-
tion, apoptosis and differentiation in normal and malig-
nant cells. The IGFs exert their growth promoting effects
through the type 1 IGF-receptors [1] A family of at least six
insulin-like growth factor binding proteins (IGFBPs) exist
in the circulation and tissues and bind to the IGFs with
high affinity [2]. A major role of these IGFBPs is to regu-
late the bioavailability of IGFs for interaction with the
type 1 IGF receptor [2]. IGFBP-3 is the predominant IGF
binding protein in plasma and together with the acid
labile subunit (ALS) sequesters approximately 90% of the
IGFs in to a 150 kDA complex that does not cross capillary
membranes. IGF complexes also exist as approximately 50
kDA complexes comprising IGFs and IGFBPs that can exit
capillaries. IGFBP-3 exists as a 43–45 kDa isoform with
high affinity for the IGFs or as an inactive 30 kDa proteo-
lytic cleaved fragment [1,3,4].
IGFBP-3 regulates cell growth by IGF-dependent [5] and
IGF-independent mechanisms [6-10]. IGFBP-3 induces
apoptosis and inhibits proliferation in human breast,
lung, prostate and colon cancer cells in vitro [6-10] and in
experimental animal models of colon carcinoma [11].
IGFBP-3 is induced by p53 in colon cancer cell lines and
is thought to play a role in anti-proliferative or pro-apop-
totic actions of p53 [12]. In some systems, IGFBP-3 is
induced by TGF-β and plays a role in TGF-β induced apop-
tosis [5,6,13-15]. The mechanisms for the IGF-independ-
ent actions of IGFBP-3 on cell functions are not fully
understood but may relate to the nuclear actions of
IGFBP-3. IGFBP-3 can translocate to the nucleus [16-18]
to regulate cell growth and modulate the expression of
genes associated with proliferation and apoptosis [7,19].
Epidemiological studies support an association between
elevated circulating levels of IGF-I and reduced IGFBP-3
levels in the circulation and increased risk of breast
[20,21], prostate [22], and colorectal cancer or adenoma
[23-26]. However, this is not consistent in all studies [27-
30]). In addition to regulating the bioavailability of
plasma IGFs, IGFBP3 is expressed locally in most if not all
tissues including the intestine [31]. The contribution of
locally expressed IGFBP-3 to pre-malignant and malig-
nant lesions in the colon is not well understood and few
studies have evaluated tissue expression of IGFBP-3 in
relation to cancer development and progression. It is also
not clear whether plasma levels of IGFBP-3 reflect levels of
expression in particular tissues such as the colon.
The present study builds on previously published findings
that low apoptosis in normal mucosa predicts elevated
risk of colorectal adenomas [32]. In the study reported
here, we evaluated the associations of plasma IGFBP-3,
and local IGFBP-3 mRNA expression with colorectal ade-
nomas or apoptosis in normal colonic mucosa. We tested
the hypothesis that low levels of plasma or tissue IGFBP-
3 will predict increased risk of adenomas and low apopto-
sis in normal colonic mucosa.
Methods
Study Population
The study population included consenting patients
enrolled in the Diet and Health Study (DHS) IV, a hospi-
tal-based cross sectional study of patients who underwent
colonoscopy for a variety of indications (39%) or screen-
ing (61%) between November 2001 and December 2002
at the University of North Carolina Hospitals (UNCH).
Participants were diverse with respect to race, socioeco-
nomic status and religion. Between November 2001 and
December 2002, a total of 3161 outpatient colonoscopies
were performed at UNC Hospitals of which 1925 subjects
were ineligible. Reasons for exclusion in the study were
incomplete examination (cecum not reached), age < 30
years, inability to give informed consent, polyposis (>100
polyps), previous colon resection or cancer, colitis (such
as ulcerative colitis and Crohn's disease) and previous
colon adenoma. Eligible participants provided informed
consent, agreed to a telephone interview, gave rectal biop-
sies during the procedure and had blood drawn. The study
was approved by the Institutional Review Board (IRB) at
the University of North Carolina School of Medicine (Pro-
tocol #05-3138).
There were 1236 subjects eligible for the study, among
whom 132 refused and 274 were not asked to participate
because the research assistant was not available. A total of
830 eligible subjects agreed to participate in the study of
which 706 completed at least one questionnaire, 669 gave
blood samples or biopsies or both. 580 had adequate
RNA quantity and quality for IGFBP-3 gene expression
analysis, and 461 had apoptosis data. The study patholo-
gist assessed and classified all colon polyps in the study
using standard pathological criteria. Cases were defined as
individuals who had one or more adenomatous polyps (n
= 164) and control subjects had no adenomatous polyps
(n = 416). There were no significant differences in demo-
graphic characteristics between eligible subjects who par-
ticipated in the study and those that did not.
Data Collection
Eligible colonoscopy patients were approached between
7:30 AM and 2:30 PM. This time was chosen to allow ade-
quate time for transporting and processing blood speci-
mens in the laboratory. At the time of colonoscopy, the
research assistant obtained consent from eligible partici-
pants, asked about the time they had their last meal and
the type of colonoscopy prep used. The assistant also
measured their waist, hips, height and weight. Informa-BMC Cancer 2008, 8:143 http://www.biomedcentral.com/1471-2407/8/143
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tion about lifestyle/diet, demographics, family history,
education, medical history, physical activity, and other
environmental factors were collected using a pre-coded
questionnaire during subsequent telephone interview.
Telephone interview was scheduled usually at a time con-
venient for the subject but no later than 12 weeks after the
colonoscopy. Diet was assessed with the NCI quantitative
Diet History Questionnaire version 1.0 (NIH Applied
Research Program, National Cancer Institute 2002). Par-
ticipants were asked to recall foods eaten, the frequency at
which they were eaten, and serving size. The nutrient
information was obtained from the NCI nutrient analysis
database and program (NIH Applied Research Program,
National Cancer Institute 2002; [33]). Lifestyle and die-
tary data were available from 678 subjects.
Biological Specimens and Laboratory Assays
The biopsy collection procedure was similar to previously
described methods [32,34]. Briefly, subjects used either a
balanced electrolyte polyethylene glycol lavage or a phos-
phate-containing purge for colonoscopy preparation. At
the beginning of the colonoscopy procedure, standard
disposable, fenetrated colonoscopy forceps (Wilson-
Cook, Winston-Salem, NC) were used to obtain six
mucosal biopsies 8–10 cm from the anal verge. Biopsies
were taken one-at-a-time from normal appearing mucosa
taking care to avoid raised lesions or larger blood vessels.
Sample sites were as uniform as possible across patients.
Blood samples were obtained from participants at the
time of colonoscopy prior to placing an IV line, and usu-
ally between 7:30 AM and 2:30 PM. Before transportation
to the laboratory, blood specimens were kept at 4°C and
were processed immediately on arrival. Plasma was sepa-
rated from the blood samples and stored in multiple aliq-
uots at -80°C until assayed. Care was taken to avoid
repeated freezing and thawing of samples. Based on ver-
bal response about last food intake and supportive evi-
dence of a clean colon, only samples from patients with
excellent colonoscopy preparation and confirmed over-
night fast were analyzed.
RNA Extraction
Four colon biopsy specimens from each participating sub-
ject were flash frozen at and stored at -80°C until
extracted. Total RNA was extracted from colon tissue spec-
imens using RNeasy kit (Qiagen, Valencia, CA) following
the manufacturer's protocol. Briefly, the tissue was
homogenized at 12,000 rpm in guanidine isothiocyanate
(GITC) containing buffer (Qiagen, Valencia, CA) using
Polytron PT-MR-3100 homogenizer with disposable
homogenizer probes to prevent cross sample contamina-
tion. The homogenate was centrifuged at 10,000 rpm for
3 minutes. The supernatant was collected and 75% etha-
nol was added to the sample to provide appropriate bind-
ing conditions and then applied to an RNeasy spin
column followed by centrifugation at 8000 rpm for 15
seconds. The column was washed three times with buffer
and the RNA was eluted in RNAse free sterile water. Total
RNA concentrations were quantified using a spectropho-
tometer at 260 nm. Mean RNA yield was 25.9 μg and was
1.1–62.0 μg. The integrity of the RNA was verified by elec-
trophoresis on ethidium bromide/agarose gels. Only sam-
ples with intact 28S and 18S RNA and no evidence of
degradation were used in this study. RNA samples were
stored in aliquots at -80°C until used for reverse transcrip-
tion and PCR.
Reverse Transcription (RT) and Real Time PCR
Reverse transcription was performed according to manu-
facturer's instructions (AMV Reverse Transcriptase,
Promega Corporation, Madison, WI). Specifically, 1 μg of
total RNA from each human colon biopsy was reverse
transcribed in a reaction mixture that contained 0.5 μg
Oligo (dT) primer in nuclease-free water (total volume of
11.5 μl), 15 units AMV reverse transcriptase (Promega,) 4
μl of 5× transcription buffer, 2 μl of 10 mM dNTPs, and 1
μl RNasin. The 20 μl reactions were incubated at 42°C for
1 hr followed by addition of 30 μl of nuclease-free water
and then heat-inactivated at 90°C for 3 minutes. A sample
of each total RNA was also processed through identical
reverse transcription reactions but without addition of
reverse transcriptase. This reaction was used as a control to
ensure that samples were free of contaminating DNA.
None of the samples showed evidence of DNA contami-
nation. The cDNA concentrations were determined by
spectrophotometry and aliquots were stored at -80°C
until used for PCR.
IGFBP-3 abundance was determined by LightCycler-based
(Roche Applied Science, Indianapolis IN) real time
polymerase chain reaction (PCR). Specific IGFBP-3 for-
ward and reverse primers and two fluorogenic hybridiza-
tion probes, one labeled with fluorescein and the other
with Light-Cycler Red 640 were designed using the Light-
Cycler Primer-Probe design software 2.0. IGFBP-3 primers
and probes were purchased from Idaho Technologies
(Idaho Technologies, Idaho Falls ID). The sequences used
to amplify a 195-bp fragment containing spanning exons
2 and exon 3 of IGFBP-3 were as follows: forward 5' AAAT-
GCTAGTGAGTCGG 3'; reverse 5'TGTCTATGGGTCTT-
GAA 3'; probe 1, 5' GATAATCATCATCAAGAAAGGGCA-
fluorescein-3'; probe 2, 5'-LC-640 red-CTAAA-
GACAGCCAGCGC 3'. The PCR reaction mix consisted of
PCR grade water to 20 μl, MgCl2 (4 mM), forward primer
(0.5 μM), reverse primer (0.5 μM), LightCycler Fast Start
DNA Master Hybprobe mix (1×), probe 1 (0.2 μM) and
probe 2 (0.4 μM) and 2 μl of cDNA template. Amplifica-
tion in the LightCycler included an initial denaturation at
95°C for 10 minutes followed by 45 cycles of denatura-
tion at 95°C for 10 seconds, annealing of forward andBMC Cancer 2008, 8:143 http://www.biomedcentral.com/1471-2407/8/143
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reverse primers to target cDNA at 57°C for 10 seconds,
and extension at 72°C for 5 seconds. During annealing,
the fluorescent probes hybridize with the product bring-
ing the fluorescein and RED 640 probes into proximity.
The two fluorescent tags communicate through FRET (flu-
orescent resonance transfer) leading to Red 640 emission,
which is directly proportional to the amount of target at
that amplification cycle.
Standards, positive and negative controls (water and non-
reverse transcribed sample) were included with PCR
amplification runs. Three internal controls were included
in each assay run. All reactions were run in triplicate on
the LightCycler 32 capillary equipment. Porphobilingen
deaminase (PBGD), a low abundance housekeeping gene
that is expressed at constant levels in a wide range of tis-
sues was used as reference. The primers and probes for
porphobilingen deaminase were purchased commercially
(Roche LightCycler hPBGD housekeeping gene set) and
the sequences are not available for proprietary reasons
(Roche Applied Science). Relative quantification was
determined using the LightCycler Relative Quantification
software (Roche Applied Science). An external cDNA
standard (calibrator) prepared from pooled RNA from
control subjects was used for relative quantification in
each PCR run. This pooled RNA also served as a constant
calibration point between PCR runs. The normalized ratio
for IGFBP3 abundance was calculated as the ratio of
IGFBP-3/PBGD for each sample divided by the IGFBP-3/
PBGD ratio of the calibrator. The intra and inter coeffi-
cient of variation for internal standards used in every assay
run were 0.7 and 3.3% for IGFBP-3 and 1.4 and 6.8% for
PBGD. No PCR products were detected when the reverse
transcriptase step was omitted.
Enzyme Immunoassays
Plasma IGFBP-3 was measured by enzyme-linked immu-
nosorbent (ELISA) assay using reagents from Diagnostic
Systems Laboratory, (Webster, Texas) according to the
manufacturer's instructions as previously described [34].
Samples were run in duplicate and the laboratory person-
nel were blinded to the case or control status of samples.
Intra-assay and inter-assay coefficients of variation for
IGFBP-3 were 4.7% and 10.2% respectively.
Assays of Apoptosis
Briefly, two colonic biopsies were fixed in 10% buffered
formalin and processed by routine histology. We assessed
apoptosis by morphological identification of apoptotic
cells on H & E stained sections in biopsies from normal
colonic mucosa. Apoptosis was confirmed on a subset of
samples by the Terminal deoxynucleotidyl Transferase
Biotin-dUTP Nick End Labeling (TUNEL) assay (ApoTag,
Intergen, Purchase, NY) as described previously [32,34].
Longitudinal crypt sections, 8–12 per biopsy were selected
and scored using previously described criteria [32,34,35].
Apoptosis was observed in isolated single epithelial cells,
distinct from lamina propria immune cells on H & E
stained sections. Apoptotic cells were recognized by cell
shrinkage, chromatin condensation and formation of
apoptotic bodies. Cells were not scored as apoptotic if the
nucleus did not meet these criteria. Apoptosis was scored
in the tissue sections by an experienced technician who
was blinded to the case-control status of the subjects. The
same reader scored selected masked slides a second time.
The intra-reader variability for morphologic determina-
tion of apoptosis was less than 1%. Apoptosis was
expressed as the average number of apoptotic bodies per
crypt counting at least 16 (and as many as 24) crypts from
2 biopsies per subject.
Statistical Analysis
For continuous variables, means and standard errors were
computed and cases and controls were compared using a
t-test. Comparison of continuous and categorical varia-
bles between adenoma cases and non-adenoma controls
were made using t-tests and Fishers Exact Test respectively.
Mean plasma IGFBP-3 or tissue IGFBP-3 mRNA was com-
pared between case and control subjects using t-tests. Cor-
relation of plasma IGFBP-3 and tissue IGFBP-3 was
assessed by Spearman's correlation coefficient. The distri-
bution of IGFBP-3 measures among control subjects were
used to generate quartile values. The highest quartile of
plasma or tissue IGFBP-3 was considered as the reference.
Apoptosis was expressed as the average number of apop-
totic bodies per crypt as described above. Using the
median in controls as cut point, we divided apoptosis
measures into low (below the median; quartiles 1 and 2
combined) and high (above the median; quartiles 3 and 4
combined) categories.
Potential confounders considered in the models were race
(white/black), sex, smoking status (current/former/
never), family history of colorectal cancer (yes/no), age,
waist/hip ratio, body mass index (BMI), NSAID usage
(uses per month over the previous five years), physical
activity (MET-minutes per day), daily calories, daily alco-
hol intake (grams per day) daily calcium (grams per day),
red meat intake (ounces per day) and fiber (grams per
day). Each co-variable was added to a logistic regression
model with adenoma case status as the response and the
variable of interest (plasma IGFBP-3 or tissue IGFBP-3) as
a predictor. A covariable was considered a potential con-
founder if it changed the parameter estimate by at least
10%. All such variables were entered into a model and a
backwards stepwise procedure was performed to deter-
mine the final model. Similar analyses were used to exam-
ine the association between apoptosis and adenomas.
Apoptosis was divided into two groups (lower half and
upper half) and was the predictor of interest. Similar pro-BMC Cancer 2008, 8:143 http://www.biomedcentral.com/1471-2407/8/143
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cedures were used for analysis of associations between
apoptosis and plasma or tissue IGFBP-3, except apoptosis
was the response instead of adenoma status and IGFBP-3
variable divided into quartiles was the predictor.
Results
Case subjects differed significantly from controls on sex,
waist-hip ratio, body mass index (BMI), alcohol, calcium
and red meat intake. There was borderline significant dif-
ference between cases and controls on age and sex. Com-
pared to controls, adenoma subjects had significantly
lower apoptosis and lower tissue IGFBP-3 mRNA (Table
1). Representative gels showing local IGFBP-3 mRNA
expression in colonic biopsies are shown in Figure 1. The
mean plasma IGFBP-3 did not differ significantly between
cases and controls or by gender or race. We divided
plasma or tissue IGFBP-3 values into quartiles based on
the distribution in controls and evaluated the association
between quartiles of plasma or tissue IGFBP-3 and adeno-
mas. The highest quartile was considered as reference.
Table 2 shows the unadjusted and adjusted odds ratios
(OR) for the associations of plasma IGFBP-3, tissue
IGFBP-3 and adenomas. For plasma IGFBP-3 only waist/
hip ratio and alcohol remained in the final model. Com-
pared to the highest quartile, the lower three quartiles of
plasma IGFBP-3 showed no significant association with
adenomas (Ptrend = 0.88). With the highest quartile as ref-
erence, low expression of IGFBP-3 mRNA in normal
mucosa showed a positive association with risk of adeno-
mas but the results did not reach statistical significance.
We observed weak but significant correlation between
plasma IGFBP-3 and tissue IGFBP-3 mRNA (Spearman's
correlation coefficient 0.12, p = 0.007). The results for the
association between apoptosis and adenomas are pre-
sented in Table 3. There were no confounders so the final
model contained only apoptosis score. Compared to sub-
jects having high apoptosis, those with low apoptosis had
a significantly increased risk of adenomas (OR 1.9 95% CI
1.2–2.8). Representative images of apoptosis in H&E
stained sections are shown in Figure 2.
We also evaluated the association between plasma IGFBP-
3 or tissue IGFBP-3 mRNA expression and apoptosis in
the normal colonic mucosa (Table 4). We observed no sig-
nificant association between plasma IGFBP-3 and apopto-
sis. Local IGFBP-3 mRNA expression was inversely
associated with apoptosis. Compared to the highest quar-
tile, those in the lowest quartile of tissue IGFBP-3 were
less likely to have low apoptosis (OR = 0.5, 95% CI 0.3,
0.8).
Discussion
We assessed whether plasma or tissue IGFBP-3 would pre-
dict the risk of colorectal adenomas or low apoptosis in
normal colonic mucosa among adenoma cases and non-
adenoma controls. Adenomas are intermediate precursors
to colorectal cancer therefore, identification of risk factors
for adenomas is desirable in order to understand and
reduce the risk of colorectal cancer. In this study we found
that low apoptosis predicted the risk of colorectal adeno-
mas thus confirming our previous observations [32] in an
independent study population. Low expression of tissue
IGFBP-3 mRNA correlated with increased risk of adeno-
mas. Surprisingly, the association of tissue IGFBP-3 and
Table 1: Descriptive Characteristics of Study participants1
Case (n = 185) Control (n = 484) p
Age (years, mean, se) 57.3 (0.7) 55.8 (0.5) 0.09
Race – White (%) 82 78 0.28
Sex – Male (%) 59 39 0.0001
Waist/Hip Ratio (mean, se) 0.93 (0.008) 0.89 (0.006) 0.0001
Body Mass Index (BMI, kg/m2 (mean, se)) 28.3 (0.4) 27.2 (0.3) 0.04
Smoking Status
Current (%) 17 10 0.09
Former (%) 37 38
Never (%) 46 51
Physical Activity(MET-minutes per day (mean, se)) 2627 (63) 2618 (37) 0.89
Family History of CRC2 (% Yes) 17 13 0.30
Alcohol grams per day (mean, se) 12.9 (1.7) 8.2 (0.7) 0.01
Daily Calories (kcal/day (mean, se)) 1926 (61) 1866 (34) 0.37
Total Calcium g per day (mean, se) 896 (37) 1039 (25) 0.003
Red Meat oz per day (mean, se) 1.78 (0.11) 1.45 (0.06) 0.01
Fiber g per day (mean, se) 20.2 (0.7) 20.5 (0.4) 0.75
Apoptosis (mean cells/crypt, se) 3.32 (0.10) 3.76 (0.06) 0.0001
Tissue IGFBP-3 (mean, se) 1.13 (0.05) 1.28 (0.05) 0.03
Plasma IGFBP-3 (ng/ml; mean, se) 2012 (68) 2001 (43) 0.89
1. Table includes participants that had tissue IGFBP-3 or plasma IGFBP-3 or both
2. Colorectal cancer (CRC)BMC Cancer 2008, 8:143 http://www.biomedcentral.com/1471-2407/8/143
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apoptosis was not as expected. Low tissue IGFBP-3 was
significantly associated with reduced risk of low apoptosis
(p = 0.04). There was no association between plasma
IGFBP-3 and adenoma risk or apoptosis. Together these
data suggest that low levels of tissue IGFBP-3 may increase
adenoma risk but is not likely to mediate the association
between low apoptosis and increased risk of adenomas.
Surprisingly, we did observe significant positive correla-
tion between plasma IGFBP-3 and tissue IGFBP-3 mRNA
expression. However, this correlation was weak (r = 0.12)
suggesting that colonic tissue IGFBP-3 levels may have
only small a contribution to plasma IGFBP-3 given that
other tissue sources also influence plasma IGFBP-3 levels.
The differential association of tissue IGFBP-3 versus
plasma IGFBP-3 with adenoma risk suggests that local
IGFBP-3 may better correlate with the functional effects in
colonic tissue compared with systemic levels.
Members of the IGF-axis play important roles in regula-
tion of cell growth and apoptosis. Plasma IGF-I is recog-
nized to have a positive association with colorectal cancer.
Plasma and tissue IGFBPs modulate the bioavailability of
IGF-I and IGF-II and possess anti-proliferative and pro-
apoptotic properties. Thus it is essential to understand the
role of both plasma and locally expressed IGF-binding
proteins in the development of neoplasia. IGF-binding
protein-3 (IGFBP-3) is major IGF binding protein and is
thought to exert a protective effect through modulation of
IGF-I bioactivity as well as through IGF-I independent
effects on cell proliferation and apoptosis [36]. The role of
local IGFBP-3 in colorectal carcinogenesis is not fully
known. Very few human studies, have investigated tissue
IGFBP-3 in the human colon and to our knowledge none
have assessed the relationship between tissue IGFBP-3
mRNA, adenomas and apoptosis. Our findings that
reduced expression of tissue IGFBP-3 mRNA in the nor-
mal colon is associated with increased risk of colorectal
adenomas are compatible with evidence in experimental
animal models indicating that elevated tissue IGFBP-3
protects against colon carcinogenesis [11]. Other studies
have shown that elevated IGFBP-3 expression is associated
RT-PCR demonstrates human 195-nucleotide (nt) IGFBP-3  products using cDNA transcribed from human colonic  biopsy RNA Figure 1
RT-PCR demonstrates human 195-nucleotide (nt) 
IGFBP-3 products using cDNA transcribed from 
human colonic biopsy RNA. cDNA samples were pre-
pared as described in Methods. GAPDH control (358 nt) is 
shown below for human samples. Controls at left are PCR 
products using IGFBP-3 standard (+ Control) and 'no reverse 
transcriptase (RT)' (-Control) cDNAs.
Controls Human cDNA Samples
+-
hBP3 (195nt)
hGAPDH (358nt)
Primers/dimers
Table 2: Association between plasma IGFBP-3 or colonic tissue IGFBP-3 and colorectal adenomas
Plasma IGFBP-3 Cases/Controls (n) Unadjusted1 OR (95% CI) Adjusted1,2 OR (95% CI) P
Quartile4 4 44/110 1.0 (Reference) 1.0 (Reference)
Quartile 3 44/109 1.0 (0.6, 1.7) 0.9 (0.5, 1.7)
Quartile 2 37/109 0.9 (0.5, 1.5) 0.9 (0.5, 1.7)
Quartile 1 47/109 1.1 (0.7, 1.8) 1.0 (0.5, 1.9)
P for linear trend 0.99 0.88
Tissue IGFBP-3 Cases/Controls (n) Unadjusted1 OR (95% CI) Adjusted1,3 OR (95% CI)
Quartile 4 30/105 1.0 (Reference) 1.0 (Reference)
Quartile 3 44/105 1.5 (0.9, 2.5) 1.5 (0.8, 2.8)
Quartile 2 43/103 1.5 (0.9, 2.5) 1.7 (0.9, 3.1)
Quartile 1 47/103 1.6 (0.9, 2.7) 1.8 (0.9, 3.3)
P for linear trend 0.07 0.06
1 Odds ratio (OR) and 95% confidence interval (CI); odds of having colorectal adenomas.
2 Adjusted for waist/hip ratio and alcohol intake for Plasma IGFBP-3.
3 Adjusted for sex and total calcium for Tissue IGFBP-3.
4 Quartile cut points based on distribution of IGFBP-3 levels among control subject. The highest quartile is considered as reference.
Table 3: Association between colorectal adenoma and 
apoptosis.
Apoptosis Cases/Controls OR (95% CI)1 P
High (Q3 & Q4)2 48/163 1.0 (Reference) --
Low (Q1 & Q2) 89/161 1.9 (1.2, 2.8) 0.003
1 Odds ratio (OR) and 95% confidence intervals (CI); odds of having 
colorectal adenomas No confounders were identified so final model 
contained only apoptosis score.
2 Q = quartile; Using the median in controls, apoptosis was divided 
into low (below the median; quartiles 1 and 2 combined) and high 
(above the median; quartiles 3 and 4 combined) categories.BMC Cancer 2008, 8:143 http://www.biomedcentral.com/1471-2407/8/143
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with reduced risk of gastric cancer [3] and prostate cancer
[37]. A recent study compared IGFBP-3 mRNA levels and
protein localization in grossly normal versus nearby
malignant colonic tissue from the same cancer patient
[38]. They found that IGFBP-3 mRNA and protein were
equivalent in normal epithelium and underlying stroma.
In cancer tissue, however, IGFBP-3 mRNA was elevated
and this reflected increased expression in the stroma but
diminished or absent expression in malignant epithelium
[15,38]. However, to our knowledge, no studies have pre-
viously evaluated tissue IGFBP-3 mRNA in normal
colonic mucosa in relation to adenoma risk. Dietary fac-
tors including sodium butyrate [38] and retinoic acid [39]
induced IGFBP-3 in gut epithelial cells as well as protect
against neoplasia. Multiple mechanisms may control
IGFBP-3 actions. For instance, factors such as P53, TGFβ
and CDX2 interact with IGFBP-3 to mediate its actions
[40-42]. TGFβ induces IGFBP-3 [5,41] and may mediate
the effects of IGFBP-3 in the colon [43]. A recent study
reported CDX2 as a transcriptional repressor of IGFBP-3,
[40] accordingly, it is possible that CDX2 and other fac-
tors interact with IGFBP-3 in the colon to promote ade-
noma development. Our findings indicate that it will be
of interest to test if IGFBP-3 levels correlate with dietary
factors such as retinoic acid or other local factors such as
TGFβ and CDX2.
Observations in experimental animal models and cell
lines indicate that IGFBP-3 is pro-apoptotic [6,11,44].
Modulators of apoptosis such as p53, TGFβ, and retinoic
acid are associated with increased levels of IGFBP-3
[5,7,13,14]. However, the exact mechanisms underlying
the actions of IGFBP-3 are not fully known. Surprisingly,
we observed that low expression of IGFBP-3 mRNA in
normal colon was associated with high apoptosis. Our
findings are intriguing. The interactions of IGFBP-3 with
other factors coupled with the complex nature of the IGF-
axis may explain our findings. A recent study found that
in vitro, IGFBP-3 enhanced TRAIL induced apoptosis in
cancer cells but did not have a similar effect on non cancer
cells [42]. Therefore, our observations may not be too sur-
prising. Accumulating evidence from other studies suggest
that IGFBP-3 alone has weak pro-apoptotic effects but
potentiates the pro-apoptotic effects of other factors [38].
In mammary epithelial cells, the pro-apoptotic effects of
Table 4: Odds ratio and 95% CI for the association between plasma IGFBP-3 or colonic tissue IGFBP-3 and apoptosis
Apoptosis1
Plasma IGFBP-3 Lower Half/Upper Half (n) Unadjusted OR (95% CI)2 P Adjusted OR (95% CI)2,3 P
Quartile 4 59/44 1.0 (Reference) -- 1.0 (Reference) --
Quartile 3 57/44 1.0 (0.6, 0.7) 0.90 1.0 (0.6, 0.7) 0.90
Quartile 2 58/45 1.0 (0.6, 0.7) 0.89 1.0 (0.6, 0.7) 0.89
Quartile 1 58/50 0.9 (0.5, 1.5) 0.60 0.9 (0.5, 1.5) 0.60
P for linear trend 0.70 0.70
Colonic tissue IGFBP-3 Lower Half/Upper Half (n) Unadjusted OR (95% CI)2 P Adjusted OR (95% CI)2,4 P
Quartile 4 63/43 1.0 (Reference) -- 1.0 (Reference) --
Quartile 3 62/51 0.8 (0.5, 1.4) 0.50 0.6 (0.3, 1.1) 0.12
Quartile 2 64/43 1.0 (0.6, 1.8) 0.96 0.8 (0.5, 1.5) 0.57
Quartile 1 51/70 0.5 (0.3, 0.8) 0.01 0.5 (0.3, 0.8) 0.009
P for linear trend 0.10 0.04
1 Number of subjects in each quartile that fall in the lower half or upper of apoptosis
2 Odds ratio (OR) and 95% confidence interval (CI), odds of being in the lower 50th percentile of apoptosis.
3 No potential confounders remained in the final model for Plasma IGFBP-3.
4 Adjusted for red meat for Tissue IGFBP-3.
Apoptosis in H&E stained sections of normal colonic epithe- lial cells Figure 2
Apoptosis in H&E stained sections of normal colonic 
epithelial cells. (A) 20×, (B) 40×. Arrows indicate apop-
totic cells.
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IGFBP-3 was limited to cancer cells [45]. Our observed
association between high tissue IGFBP-3 mRNA and
reduced risk of adenomas may therefore reflect different
or indirect effects of IGFBP-3 on apoptosis. The precise
relationship between tissue IGFBP-3 and apoptosis in the
normal human colon appears to be complex. Additional
studies are needed to confirm our findings.
Several studies suggest an inverse association between
plasma IGFBP-3 and risk of cancer in a number of organs
[1,3,20,46,47]. However, this has not been consistently
observed by all studies [29]. In some studies, elevated
plasma IGF-I was associated with increased risk of color-
ectal adenomas while inverse associations were reported
for plasma IGFBP-3 [25,48]. Teramukai et al. 2002 [49]
also found a modest inverse association between colorec-
tal adenomas and high plasma levels of IGFBP-3. We
observed no significant association between plasma
IGFBP-3 and adenomas or plasma IGFBP-3 and apoptosis
in this patient population. Our study highlights the
importance of considering plasma as well as tissue IGFBP-
3 in the early stages of colon tumor development, consist-
ent with recent reports on tissue IGFBP-3 in colon cancer
[38].
Conclusion
In summary, we found that tissue IGFBP-3 but not plasma
IGFBP-3 was associated with modestly elevated risk of
colorectal adenomas. Our findings suggest that low local
IGFBP-3 expression may increase adenoma risk but is not
likely to mediate the relationship between adenomas and
apoptosis.
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